Males with Reifenstein syndrome have partial androgen insensitivity; they are born with external male sex features. Affected men often present for clinical workup at the time of puberty, with the following physical characteristics and/or complaints [1] [2]:

• Small and/or abnormal male genitals (e.g., small penis, small scrotum, incompletely closed or undescended testicles) [3]
• Gynecomastia
• Sparse facial hair and difficulty growing a beard (normal amount of pubic and axillary hair)
• Complaints of sexual dysfunction
• Inability to impregnate female partner due to infertility

It is important to note a contrast of presenting symptoms between men with Reifenstein syndrome (partial androgen insensitivity) to those with complete androgen insensitivity. Men with complete androgen insensitivity often present with external female sex characteristics (without a uterus), internal male sex characteristics (e.g., undescended testes), and absent or very little pubic or axillary hair.

Diagnosis of Reifenstein syndrome consists of a history, physical findings, blood tests, genetic tests, sperm count, and less often a testicular biopsy. Physical findings include varying degrees of ambiguous external genitalia, small penis and scrotum, undescended testes, space facial hair, and gynecomastia. Affected individuals may also have partially developed female sex organs, a small or missing vas deferens.

Blood tests for various sex hormones (testosterone and its derivatives, anti-müllerian hormone, sex hormone-binding globulin, luteinizing hormone) are often performed. Prior to puberty, laboratory tests will reflect normal levels of testosterone, dihydrotestosterone, and luteinizing hormone. Following puberty, there may be normal or elevated testosterone with elevated levels of luteinizing hormone. Additionally, either during the first year of life or the following puberty, men will often have elevated levels of anti-müllerian hormone [4].

An abdomen/pelvic ultrasound is the most useful radiological test. Findings commonly demonstrate the absence of a uterus, impaired development of prostate and Wolffian duct derivatives, and undescended testes [5] [6] [7]. In rare instances where there is a palpable mass or otherwise clinically indicated, a magnetic resonance imaging may be used to visualize the pelvic anatomy.

Genetic analysis will show a normal 46 XY chromosomal pattern. Genetic defects in the androgen receptor (AR) gene cause androgen insensitivity syndrome by preventing the androgen receptors from functioning correctly. A mutation of the AR gene causes cells to be less responsive or refractory to androgens. Androgens and androgen receptors also play a role in hair growth and libido. Depending on the degree of mutation of the AR gene, an affected individual's sex characteristics can vary from mostly female to mostly male [8] [9] [10] [11]. A DNA analysis of the androgen receptor gene will detect any mutations in the AR gene. The number of CAG repeats in exon 1 of the AR gene have been shown to be inversely proportional to the transcriptional activity of the androgen target gene; in other words, the greater the number of trinucleotide CAG repeats, the greater the degree of androgen insensitivity.

Treatment for Reifenstein Syndrome is tailored to the individual's specific needs and symptoms. Hormone replacement therapy may be used to promote the development of secondary sexual characteristics. Surgical interventions might be considered to correct hypospadias or undescended testes. Psychological support and counseling are important components of care, helping individuals and families navigate the complexities of the condition. Fertility options may also be discussed, as infertility is common.

The prognosis for individuals with Reifenstein Syndrome varies depending on the severity of the condition and the effectiveness of treatment. With appropriate medical and psychological support, many individuals can lead healthy and fulfilling lives. However, challenges such as infertility and social or psychological issues related to gender identity may persist. Early diagnosis and intervention can improve outcomes and quality of life.

Reifenstein Syndrome is caused by mutations in the androgen receptor (AR) gene, which is located on the X chromosome. These mutations impair the body's ability to respond to androgens, leading to the characteristic symptoms of the syndrome. The condition is inherited in an X-linked recessive pattern, meaning it primarily affects males, while females can be carriers of the gene mutation.

Reifenstein Syndrome is a rare condition, with an estimated incidence of 1 in 20,000 to 1 in 99,000 male births. Due to its rarity and the variability in presentation, it is possible that the condition is underdiagnosed. The syndrome affects individuals of all ethnic backgrounds, and there is no known geographic predilection.

The pathophysiology of Reifenstein Syndrome involves a defect in the androgen receptor, which is crucial for mediating the effects of male sex hormones. Mutations in the AR gene lead to a partial inability of cells to respond to androgens, resulting in incomplete masculinization of the external genitalia and other features. The degree of insensitivity can vary, leading to a spectrum of clinical presentations.

Currently, there is no known way to prevent Reifenstein Syndrome, as it is a genetic condition. Genetic counseling is recommended for families with a history of the disorder, to understand the risks and implications of passing the condition to offspring. Prenatal testing and carrier screening may be options for families at risk.

Reifenstein Syndrome is a rare genetic disorder characterized by partial insensitivity to androgens, leading to a range of physical manifestations in affected males. Diagnosis involves clinical evaluation, hormonal testing, and genetic analysis. Treatment is individualized and may include hormone therapy, surgery, and psychological support. While the condition presents challenges, early intervention can improve quality of life.

For patients and families affected by Reifenstein Syndrome, understanding the condition is crucial. It is a genetic disorder that affects male sexual development due to the body's reduced ability to respond to male hormones. Symptoms can vary widely, and treatment is tailored to each individual's needs. Support from healthcare providers, including genetic counseling and psychological services, can help manage the condition and its implications.

1. Hannema SE, Scott IS, Rajpert-De Meyts E, Skakkebaek NE, Coleman N, Hughes IA. Testicular development in the complete androgen insensitivity syndrome. J Pathol. 2006;208:518–27.
2. Gottlieb B, Pinsky L, Beitel LK, Trifiro M. Androgen insensitivity. Am J Med Genet. 1999;89:210-7.
3. Van Batavia JP, Kolon TF. Fertility in disorders of sex development: A review.J Pediatr Urol. 2016 Nov 3. [Epub ahead of print] Review
4. Sinnecker GH, Hiort O, Nitsche EM, Holterhus PM, Kruse K. Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene. German Collaborative Intersex Study Group. Eur J Pediatr. 1997;156:7–14.
5. Galani, A, Kitsiou-Tzeli S, Sofokleous C, Kanavakis E, Kalpini-Mavrou A. Androgen insensitivity syndrome: clinical features and molecular defects. Hormones (Athens). 2008; 7:217-29.
6. Quigley CA, Bellis AD, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev.1995;16:271-321.
7. Turan V, Yeniel O, Ergenoğlu M, Terek C, Ulukuş M. Incomplete androgen insensitivity (Reifenstein syndrome) - a case report.J Turk Ger Gynecol Assoc. 2010;11:110-2.
8. Griffin JE. Androgen resistance--the clinical and molecular spectrum.N Engl J Med. 1992;326:611.
9. Chen MJ, Vu BM, Axelrad M, et al. Androgen Insensitivity Syndrome: Management Considerations from Infancy to Adulthood. Pediatr Endocrinol Rev. 2015;12:373-87.
10. Gottlieb B, Pinsky L, Beitel LK, Trifiro M. Androgen insensitivity. Am J Med Genet. 1999;89:210-7.
11. Hiort O. Clinical and molecular aspects of androgen insensitivity. Endocr Dev. 2013;24:33-40.